Apomorphine in the treatment of Parkinson's disease: a review

Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and continuous process with direct impact on patients' quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment.

[1]  T. van Laar,et al.  Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. , 2017, Parkinsonism & related disorders.

[2]  Á. Sesar,et al.  Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients , 2017, Journal of Neurology.

[3]  M. Vérin,et al.  Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations , 2017, Journal of the Neurological Sciences.

[4]  W. Poewe,et al.  Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's. , 2016, Parkinsonism & related disorders.

[5]  K. Ray Chaudhuri,et al.  Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future , 2016, npj Parkinson's Disease.

[6]  M. Lanotte,et al.  Advanced therapies in Parkinson's disease: Long-term retrospective study. , 2016, Parkinsonism & related disorders.

[7]  A. Lees,et al.  Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. , 2016, Parkinsonism & related disorders.

[8]  A. Fasano,et al.  24‐Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[9]  E. Dietrichs,et al.  Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. , 2015, Parkinsonism & related disorders.

[10]  M. Okun,et al.  The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease , 2015, Expert opinion on pharmacotherapy.

[11]  G. Deuschl,et al.  Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. , 2015, Parkinsonism & related disorders.

[12]  C. Redecker,et al.  Advanced stages of PD: interventional therapies and related patient-centered care , 2015, Journal of Neural Transmission.

[13]  T. Henriksen Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians. , 2014, Neurodegenerative disease management.

[14]  C. N. Homann,et al.  The role of subcutaneous infusion of apomorphine in Parkinson’s disease , 2014, Expert review of neurotherapeutics.

[15]  E. Molho,et al.  Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions , 2014, Expert review of neurotherapeutics.

[16]  J. Kulisevsky,et al.  Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I) , 2013 .

[17]  H. Reichmann,et al.  Treatment of Parkinson’s disease in the advanced stage , 2013, Journal of Neural Transmission.

[18]  J. Kulisevsky,et al.  Advanced Parkinson ’ s disease : Clinical characteristics and treatment ( part 1 ) , 2013 .

[19]  G. Deuschl,et al.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.

[20]  W. Ondo,et al.  Apomorphine injections: predictors of initial common adverse events and long term tolerability. , 2012, Parkinsonism & related disorders.

[21]  A. Albanese,et al.  Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation , 2012, European journal of neurology.

[22]  K. Chaudhuri,et al.  Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.

[23]  R. Hilker,et al.  What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? , 2011, Journal of Neural Transmission.

[24]  F. Klostermann,et al.  Benefit from jejunal levodopa in a patient with apomorphine pump , 2011, Journal of Neurology.

[25]  D. Nyholm,et al.  Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.

[26]  S. Gunzler Apomorphine in the treatment of Parkinson disease and other movement disorders , 2009, Expert opinion on pharmacotherapy.

[27]  K. Kieburtz Therapeutic strategies to prevent motor complications in Parkinson’s disease , 2008, Journal of neurology.

[28]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[29]  M. Stacy,et al.  Apomorphine in the treatment of Parkinson's disease , 2007, Expert opinion on pharmacotherapy.

[30]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[31]  R. Pfeiffer,et al.  Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. , 2007, Parkinsonism & related disorders.

[32]  Jack J. Chen,et al.  Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease , 2006, Pharmacotherapy.

[33]  Andrew Evans,et al.  Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges , 2005, Movement disorders : official journal of the Movement Disorder Society.

[34]  E. Tolosa,et al.  Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[35]  Andrew J Lees,et al.  Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients , 2002, Movement disorders : official journal of the Movement Disorder Society.

[36]  D. Nyholm,et al.  Duodenal levodopa infusion in Parkinson's disease – long‐term experience , 2001, Acta neurologica Scandinavica.

[37]  A. Lees,et al.  Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. , 2001, Brain : a journal of neurology.

[38]  Use of apomorphine in Parkinson's disease. , 1999, Hospital medicine.

[39]  P. Odin,et al.  Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.

[40]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[41]  A. Lees,et al.  Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications , 1998, Neurology.

[42]  I. McKeith,et al.  Psychiatric features in diffuse Lewy body disease , 1998, Neurology.

[43]  L. Metman,et al.  Apomorphine responses in parkinson's disease and the pathogenesis of motor complications , 1997, Neurology.

[44]  A. Lees,et al.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[45]  A J Lees,et al.  Dopamine agonists in Parkinson's disease: a look at apomorphine , 1993, Fundamental & clinical pharmacology.

[46]  A. Hughes,et al.  Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years , 1993, Movement disorders : official journal of the Movement Disorder Society.

[47]  A. Lees,et al.  Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. , 1991, Clinical neuropharmacology.

[48]  A. Lees,et al.  Intranasal apomorphine in Parkinson's disease , 1991, Neurology.

[49]  A. Lees,et al.  The Motor Response to Repeated Apomorphine Administration in Parkinson's Disease , 1991, Clinical neuropharmacology.

[50]  A. Lees,et al.  The motor response to sequential apomorphine in parkinsonian fluctuations. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[51]  A. Hughes,et al.  Rectal apomorphine in Parkinson's disease , 1991, The Lancet.

[52]  A. Lees,et al.  Intranasal apomorphine: a new treatment in Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[53]  A. Lees,et al.  Comparison of motor response to apomorphine and levodopa in Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[54]  A. Lees,et al.  Apomorphine in the diagnosis and treatment of parkinsonian tremor. , 1990, Clinical neuropharmacology.

[55]  A. Lees,et al.  Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes , 1990, The Lancet.

[56]  A. Lees,et al.  Subcutaneous apomorphine in the treatment of Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[57]  R. Duvoisin,et al.  Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism , 1988, Annals of neurology.

[58]  A. Lees,et al.  SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS , 1988, The Lancet.

[59]  I. Shoulson,et al.  Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations , 1986, Annals of neurology.

[60]  A. Lees,et al.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. , 1984, Brain : a journal of neurology.

[61]  M. Elian,et al.  MOTOR-NEURONE DISEASE IN ISRAEL , 1975, The Lancet.

[62]  G C Cotzias,et al.  Similarities between neurologic effects of L-dopa and of apomorphine. , 1970, The New England journal of medicine.

[63]  Schwab Rs,et al.  Apomorphine in Parkinson's disease. , 1951 .

[64]  J. Lettvin,et al.  Apomorphine in Parkinson's disease. , 1951, Transactions of the American Neurological Association.